AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference

Audio By Carbonatix

MASON, Ohio--(BUSINESS WIRE)--Nov 18, 2025--

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 37 th Annual Healthcare Conference.

AtriCure’s management is scheduled to participate in a fireside discussion on Tuesday, December 2, 2025, at 10:00 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251118408743/en/

CONTACT: Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

[email protected] Bych

Gilmartin Group

Investor Relations

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA OHIO

INDUSTRY KEYWORD: BIOTECHNOLOGY FDA ALTERNATIVE MEDICINE HEALTH SURGERY OTHER SCIENCE RESEARCH MEDICAL DEVICES HOSPITALS GENETICS SCIENCE CLINICAL TRIALS CARDIOLOGY MEDICAL SUPPLIES

SOURCE: AtriCure, Inc.

Copyright Business Wire 2025.

PUB: 11/18/2025 08:00 AM/DISC: 11/18/2025 07:59 AM

http://www.businesswire.com/news/home/20251118408743/en